Information Provided By: 
Fly News Breaks for December 16, 2019
HZNP
Dec 16, 2019 | 07:51 EDT
Jefferies analyst David Steinberg increased his price target on Horizon Pharma shares to $40 from $35 after an FDA advisory committee voted 12-0 that the benefits of teprotumumab outweigh the potential risks in treating thyroid eye disease, or TED. While acknowledging that the FDA is not bound by this recommendation, Steinberg sees it as "a strong signal" for approval ahead of the drug's March 8, 2020 PDUFA action date, he tells investors. He keeps a Buy rating on Horizon shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
